Kongressthemen As immuno-oncology drug development transforms cancer treatment paradigms, preclinical and clinical data continues to demonstrate that the TIGIT axis blockade, particularly in combination with other immune checkpoint inhibitor partners, has strong efficacy. Despite recent clinical setbacks, and with at least 15 anti-TIGIT axis drugs in active clinical development, TIGIT axis targeting remains a promising treatment approach.
Wissenschaftliche Fach-Gesellschaft Hanson Wade
Anmerkungen Speakers: Murali Ramachandra, Chief Executive Officer, Aurigene Discovery Technologies, David Wald, Associate Professor, Case Western Reserve University, Leonie Meima, Vice President Business Development, Coherus Biosciences
Kongressgebühr Conference Only - Industry Pricing - On the Day : USD 2299.00,
Conference Only - Academic Pricing - On the Day: USD 2099.00,
Conference Only - Service and Solution Provider Pricing - On the Day: USD 2799.00
Veranstalter Kontakt 83 Great Titchfield Street W1W 6RH London Großbritannien